Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
people with cardiovascular disease, in this paper
Already taking combination therapy of sulfonylureas and metformin, or nottheir own situation, not assigned
on combination therapy of sulfonylureas and metformin
diet therapy, metformin monotherapy, or sulfonylurea monotherapy
No clear link with deaths+19%
No clear link with CVD deaths1.3×
Combination therapy of sulfonylureas and metformin went with more composite end point of CVD hospitalizations or deaths+43%
correlation, not a testthe abstract, start to end
… of sulfonylureas and metformin were 1.19 (0.88-1.62) for all-cause mortality, 1.29 (0.73-2.27) for CVD mortality, and 1.43 (1.10-1.85) for a composite end …
← favours treatmentfavours comparator →
could be chanceAll-cause mortalitycombination therapy of sulfonylureas and metformin vs diet therapy, metformin monotherapy, or sulfonylurea monotherapy
RR 1.190.88–1.62
CVD mortalitycombination therapy of sulfonylureas and metformin vs diet therapy, metformin monotherapy, or sulfonylurea monotherapy
RR 1.290.73–2.27
Composite end point of CVD hospitalizations or mortality (fatal or nonfatal events)combination therapy of sulfonylureas and metformin vs diet therapy, metformin monotherapy, or sulfonylurea monotherapy
RR 1.431.10–1.85
MetforminSulfonylureas & glinidesAll-cause mortalityAdverse events & safety
1 / 4